Generis partners Kyowa Kirin

Japanese Pharmaceutical Group Kyowa Kirin is now using Generis CARA™ Life Science Platform from Generis (www.generiscorp.com) to enable it to respond quickly and consistently to regulatory correspondence and reduce time to market.

Kyowa Kirin will use Generis' CARA platform for ongoing work to answer questions from healthcare authorities around the world leveraging the powerful automation and translation capabilities of the CARA Life Science Platform to capture, review and answer regulatory questions.  

Questions will be extracted individually from the incoming documents, and then translated into multiple languages, providing Kyowa Kirin with a multilingual database of questions from medical authorities, so that users around the world can find answers in any language.

“We are delighted to have the opportunity to work with Kyowa Kirin to bring their products to market using the CARA Life Sciences Platform to ensure consistent Health Authority communications while reducing the burden of day-to-day operations,” comments James Kelleher, CEO, Generis.

The CARA Life Sciences Platform has seen a flurry of activity over the past few months as pharmaceutical companies seek to streamline the management and publication of regulatory, quality, safety and clinical information/content using a consistent global platform that can be easily configured to suit each new use case.  

Over 60% of the top 20 life sciences companies rely on Generis’ flagship CARA™ Life Science Platform for critical document and information management, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer, and Merck KGaA.